{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:25:46Z","timestamp":1765887946871,"version":"3.37.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1124\/dmd.117.078006","type":"journal-article","created":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T19:30:28Z","timestamp":1510169428000},"page":"109-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin"],"prefix":"10.1016","volume":"46","author":[{"given":"Helen","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Dutreix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Rebello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taoufik","family":"Ouatas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dung Yu","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi J.","family":"Einolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.117.078006_bib1","first-page":"5353","article-title":"Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251","volume":"52","author":"Andrejauskas-Buchdunger","year":"1992","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.117.078006_bib2","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1182\/blood-2007-07-101238","article-title":"Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin","volume":"110","author":"Barry","year":"2007","journal-title":"Blood"},{"key":"10.1124\/dmd.117.078006_bib3","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1124\/dmd.113.052316","article-title":"Comparison of endogenous 4\u03b2-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin","volume":"41","author":"Bj\u00f6rkhem-Bergman","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078006_bib4","doi-asserted-by":"crossref","first-page":"38685","DOI":"10.1074\/jbc.M105127200","article-title":"Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4","volume":"276","author":"Bodin","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.117.078006_bib5","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/dmd.117.078006_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.117.078006_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00228-014-1675-0","article-title":"Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin","volume":"70","author":"Dutreix","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/mol.113.085092","article-title":"Tumor suppressor protein p53 negatively regulates human pregnane X receptor activity","volume":"83","author":"Elias","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib42","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1124\/dmd.113.052225","article-title":"Critical review of preclinical approaches to investigate cytochrome P450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper","volume":"41","author":"Evers","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078006_bib12","unstructured":"European Medicines Agency (EMA) (2012) Committee for Human Medicinal Products (CHMP) Guideline on the investigation of drug interactions. June 21, 2012. European Medicines Agency, London."},{"key":"10.1124\/dmd.117.078006_bib13","first-page":"17","article-title":"PKC412--a protein kinase inhibitor with a broad therapeutic potential","volume":"15","author":"Fabbro","year":"2000","journal-title":"Anticancer Drug Des"},{"key":"10.1124\/dmd.117.078006_bib14","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"year":"2012","series-title":"Drug Interaction Studies\u2014Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations: Guidance for Industry","key":"10.1124\/dmd.117.078006_bib15"},{"key":"10.1124\/dmd.117.078006_bib16","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/jps.21802","article-title":"Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates","volume":"99","author":"Fenneteau","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.117.078006_bib17","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.117.078006_bib19","first-page":"73","article-title":"Midostaurin: an emerging treatment for acute myeloid leukemia patients","volume":"7","author":"Gallogly","year":"2016","journal-title":"J Blood Med"},{"key":"10.1124\/dmd.117.078006_bib20","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0091270011419850","article-title":"Effect of telaprevir on the pharmacokinetics of midazolam and digoxin","volume":"52","author":"Garg","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/carcin\/bgs318","article-title":"Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53","volume":"34","author":"Goldstein","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.117.078006_bib22","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"key":"10.1124\/dmd.117.078006_bib23","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.117.078006_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-008-0842-3","article-title":"Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor","volume":"64","author":"Harmsen","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.117.078006_bib26","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1038\/psp.2014.18","article-title":"Evaluation of 4beta-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model","volume":"3","author":"Leil","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib27","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"key":"10.1124\/dmd.117.078006_bib28","unstructured":"Lin Z, Fahmi OA, Johnson N, Rodrigues DA, Obach RS, Steyn SJ, Zientek M, Goosen TC (2016) Tyrosine kinase inhibitors robustly induced CYP3A4 mRNA, but not activity via multiple pathways, in 21st International Symposium on Microsomes and Drug Oxidations; 2016 October 2\u20136; Davis, CA. International Society for the Study of Xenobiotics, Washington, DC."},{"key":"10.1124\/dmd.117.078006_bib29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/cpdd.265","article-title":"Compelling relationship of CYP3A induction to levels of the putative biomarker 4\u03b2-hydroxycholesterol and changes in midazolam exposure","volume":"5","author":"Mangold","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1124\/dmd.117.078006_bib30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome","volume":"104","author":"Meyers","year":"2005","journal-title":"Cancer"},{"key":"10.1124\/dmd.117.078006_bib31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","article-title":"Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C","volume":"19","author":"Propper","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.117.078006_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug-drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J"},{"key":"10.1124\/dmd.117.078006_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.117.078006_bib34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/dmd.117.078006_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2004-03-0891","article-title":"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412","volume":"105","author":"Stone","year":"2005","journal-title":"Blood"},{"key":"10.1124\/dmd.117.078006_bib36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V126.23.6.6","volume":"126","author":"Stone","year":"2015","journal-title":"Blood"},{"key":"10.1124\/dmd.117.078006_bib37","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.23785","article-title":"The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"113","author":"Tsimberidou","year":"2008","journal-title":"Cancer"},{"key":"10.1124\/dmd.117.078006_bib38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0091270008318006","article-title":"Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus","volume":"48","author":"Wang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.117.078006_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1124\/dmd.117.078006_bib40","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jps.23818","article-title":"Equilibrium gel filtration to measure plasma protein binding of very highly bound drugs","volume":"103","author":"Weiss","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.117.078006_bib41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/0003088-200847120-00005","article-title":"A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects","volume":"47","author":"Yin","year":"2008","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624054527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.117.078006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:33:36Z","timestamp":1739903616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624054527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0090955624054527"],"URL":"https:\/\/doi.org\/10.1124\/dmd.117.078006","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.117.078006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}